. . . "Investigated for use/treatment in pulmonary hypertension, connective tissue diseases, hypertension, and congestive heart failure."@en . . . . "approved"@en . . "investigational"@en . . . "Take without regard to meals"@en . "Sitaxentan"@en . . . . . . . "210421-64-0"@en . "99% +"@en . . . . . "70-100%"@en . . . . . . . . "Sitaxentan is a competitive antagonist of endothelin-1 at the endothelin-A (ET-A) and endothelin-B (ET-B) receptors. Under normal conditions, endothelin-1 binding of ET-A or ET-B receptors causes pulmonary vasoconstriction. By blocking this interaction, Sitaxentan decreases pulmonary vascular resistance. Sitaxentan has a higher affinity for ET-A than ET-B."@en . . "Renal (50 to 60%) Fecal (40 to 50%)"@en . . "Thelin"@en . . "Sitaxsentan"@en . "10 hours"@en . . . . . . . . . "Sitaxentan"@en . . . . . . .